Psychedelics INVI MindHealth and ŌURA gauge psychedelic therapy impact among veterans US$4 million in federal funding has been secured for the endeavour Rowan Dunne6 days ago
Psychedelics Psilera raises US$8.8M to fight dementia with non-psychoactive psilocybin drug The biotech is preparing for in-human trials with 'PSIL-006' next year Rowan DunneMay 29, 2026
Psychedelics Small-scale Nature study shows psilocybin causes brain changes after one use Compass Pathways provided the synthetic compound used in the research process Rowan DunneMay 7, 2026
Psychedelics XTL Biopharma to enter psychedelics sector with Psyga Bio takeover The move was significantly inspired by Trump's recent executive order Rowan DunneMay 4, 2026
Psychedelics Compass Pathways scores FDA priority voucher for synthetic psilocybin drug Three companies were awarded the vouchers after Trump's executive order was signed Rowan DunneApril 30, 2026
Psychedelics Optimi Health launches ibogaine initiative in response to Trump’s executive order Psychedelic stocks surged after the president gave his signature Rowan DunneApril 21, 2026
Psychedelics Trump prepares to sign executive order for expedited ibogaine research Sources just informed CBS News about the significant development Rowan DunneApril 17, 2026
Cannabis Bioxyne to manufacture Aurora Cannabis products for international distribution The company went from a one-person operation to partnering with one of the world's cannabis majors Rowan DunneApril 6, 2026
Psychedelics Israeli scientists get tobacco to produce array of psychedelic compounds The novel method has significant implications for clinical psychedelic drug production Rowan DunneApril 2, 2026
Psychedelics Deutsche Bank initiates bullish coverage of psychedelics company AtaiBeckley The financial institution has given the drug developer a Buy rating a US$12 share target Rowan DunneMarch 31, 2026